CSL Limited

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. Please help improve it by replacing them with more appropriate citations to reliable, independent, third-party sources. (February 2016) (Learn how and when to remove this message) This article needs to be updated. Please help update this article to reflect recent events or newly available information. (November 2020) (Learn how and when to remove this message)

CSL Limited

Company type	Public
Traded as	ASX: CSL S&P/ASX 200 component
Industry	Biotechnology
Founded	1916 (Federal government department), 1994 (privatised)
Headquarters	Parkville, Melbourne, Victoria, Australia (Global),[1]
Key people	Paul McKenzie (CEO)
Products	blood plasma, vaccines, antivenom, other laboratory and medical products
Revenue	US$10.61 billion (2021))[2]
Net income	US$1.919 billion (2021)[2]
Number of employees	30,000 person (2021)[2]
Divisions	CSL Behring CSL Plasma CSL Seqirus CSL Vifor
Website	www.csl.com

CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications.^[3] The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994.